The Exploratory Study of Electroacupuncture in the Treatment of Peripheral Neuropathy Induced by Platinum Based Chemotherapy Drugs

Tianjin Medical University Cancer Institute and Hospital0 sites72 target enrollmentFebruary 10, 2018

ConditionsChemotherapy-induced Peripheral Neuropathy

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Chemotherapy-induced Peripheral Neuropathy
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Enrollment: 72
Primary Endpoint: Quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy (QLQ-CIPN20)
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Through the research to confirm the effectiveness and safety of using electroacupuncture in the treatment of chemotherapy-induced peripheral neuropathy.

Registry

clinicaltrials.gov

Start Date

February 10, 2018

End Date

November 1, 2018

Last Updated

8 years ago

Study Type

Interventional

Study Design

Crossover

Sex

All

Investigators

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•The histopathological and / or cellular pathology results prove malignancy of the tumor and the patient has received chemotherapy treatment before.
•15weeks after the completion of chemotherapy, the limbs are still feeling abnormal and the symptoms fulfill World Health Organization (WHO) grade 2 or more.
•zubrod - Eastern Cooperative Oncology Group-WHO (ZPS) grade 0-2, cardiac function, liver function and renal function are not significantly abnormal, the survival period of the patient is expected to be more than 6 months.
•Gender unrestricted, aged between 18 to 80 years old.
•Voluntary participation in the study, will to sign informed consent, willing to comply with randomized grouping, will to follow-up.

Exclusion Criteria

•Patients who suffer from peripheral neuropathy due to infection, radiotherapy, HIV, chronic alcoholism, hypothyroidism, diabetes, paraneoplastic syndrome or other diseases; or are suffering from nervous system diseases.
•Patients who are being treated with other drugs that may lead to neurotoxicity .
•Patients with blood coagulation disorder.
•Pregnancy and lactating women.
•Patients with infection, scarring or defects near the acupoint sites.
•Received intervention for the prevention and treatment of peripheral neuropathy 2 weeks before screening or has received traditional Chinese medicine (acupuncture, moxibustion, cupping, Chinese medicine therapy one month before.